CompletedNCT03292848
Single-Dose Brexpiprazole Safety and Pharmacokinetics in Children
About this title
Read the official source — NCT03292848Medication studyAges 6–12United StatesADHD
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Little Rock and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: October 10, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT03292848
- Official title
Show the full official title
A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Rogers · Long Beach
4 more locations
- Charlotte
- Oklahoma City
- San Antonio
- Orem
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Brexpiprazole.
Who was this study for?
Listed age limits: 6 years to 12 years.
